



AGENIX LIMITED

爱健克斯有限公司

(ASX: AGX)

ABN 58 009 213 754
465 Auburn Road,
Hawthorn East, Vic, 3123
Australia
www.agenix.com

ASX MEDIA RELEASE

23 March 2011

TRANSFER OF SHARE REGISTRY – AGENIX LIMITED (AGX)

Agenix Limited (ASX: AGX) (**Agenix**), advises wish to announce that effective 4 April 2011 our company register will be transferred to:

Advanced Share Registry Services Limited
150 Stirling Highway
Nedlands, WA 6009

Telephone: 08 9389 8033
Facsimile: 08 9389 7871

Our register is currently maintained by Computershare Investor Services Pty Limited.

About Agenix Limited

Agenix is a publicly listed, Australian based international biotechnology company with a wholly owned subsidiary in China. The company has two core businesses:

- In **Innovative Biopharmaceuticals**, Agenix has 'in principal' rights to clinically develop a pipeline of innovative and proprietary anti-viral therapies for commercialisation in China. Through its wholly owned subsidiary, Agenix Biopharmaceutical (Shanghai), established in 2007, the company has established a collaboration with the Institute of Medicinal Biotechnology (**IMB**) of the Chinese Academy of Medical Sciences in Beijing to develop and commercialise AGX-1009, a next-generation, patented prodrug analog of an existing compound for the treatment of chronic HBV in China. AGX-1009 belongs to a new class of drugs called Nucleotide Analogue Reverse Transcriptase Inhibitors (NtRTI).
- In **Medical Diagnostics**, the company's lead indicator is a patented monoclonal antibody diagnostic called Thromboview® that, uniquely, detects live blood clots (DVT and PE) in the human body. ThromboView® has successfully completed two FDA Phase II human clinical trials in the United States. The company is positioning Thromboview® as an innovative diagnostic (a 'theranostic') to support the use of Novel Oral Anti-Coagulants and is seeking a development partner to commercialise the indicator.

Agenix has been listed on the Australian Securities Exchange (ASX: AGX) since 1987. Agenix is active in China, and seeking to establish commercial partnerships in the rest of the world. For additional information on Agenix Limited, please visit the company's website at agenix.com

Yours faithfully,

A handwritten signature in black ink that reads "Nick Weston".

Nicholas Weston

Executive Chairman

Enclosures: Nil

CONTACT: Investor relations: Gary Taylor
+61 (0) 467 559 037 or email cfo@agenix.com